The FDA has given BIOTRONIK approval to introduce the company’s Acticor and Rivacor lines of high-voltage cardiac rhythm implants. They’re designed to treat tachycardia (likely supraventricular tachycardia (SVT) and have been made to be smaller and have a longer battery life. Some of the implants have a nearly 15 year lifetime, helping (Read more...)